Rocket One, Inc (HOTH) Stock
Rocket One, Inc. engages in the development of new generation therapies for dermatological disorders.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About Rocket One, Inc
Rocket One, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in Hoboken, NJ.
Rocket One, Inc is led by CEO Robb Knie, employs 2 people, headquartered in US, publicly traded since 2019.
Rocket One, Inc (HOTH) stock trades at $1.13 with a market capitalization of $14.92M. The stock is valued at a price-to-earnings (P/E) ratio of -0.70, price-to-book of 1.40, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.49 and $2.45, and currently trades 53.9% below its 52-week high.
On profitability, Rocket One, Inc generates a return on equity (ROE) of -200.00%, return on capital employed of -157.14%, an operating margin of 0.00%, a net profit margin of 0.00%.